Loading
Cinrebafusp alfa is an experimental fusion protein from Pieris Pharmaceuticals in phase 2 trials for gastric & gastro-oesophageal junction cancer, aimed at HER2.
Cinrebafusp alfa (PRS-343) is a fusion protein developed by Pieris Pharmaceuticals. Its target is HER2 (the sponsor names HER2 x 4-1BB). The sponsor states: Cinrebafusp alfa (PRS-343) is a HER2/4-1BB bispecific anticalin-antibody fusion protein that binds HER2 on tumour cells while engaging 4-1BB (CD137) to costimulate T cells. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in gastric & gastro-oesophageal junction cancer. The largest, NCT05190445, plans to enrol 80 participants with primary completion was scheduled for 2023-02-01 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Cinrebafusp alfa (PRS-343) is a HER2/4-1BB bispecific anticalin-antibody fusion protein that binds HER2 on tumour cells while engaging 4-1BB (CD137) to costimulate T cells. Connects to HER2 and CD137 (4-1BB, TNFRSF9).
1.Cinrebafusp alfa binds HER2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Cinrebafusp alfa" OR ABSTRACT:"Cinrebafusp alfa" OR TITLE:"PRS-343" OR ABSTRACT:"PRS-343" OR TITLE:"Cinrebafusp alfa PRS-343" OR ABSTRACT:"Cinrebafusp alfa PRS-343") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cinrebafusp alfa, not a curated reading list.
Shares HER2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares HER2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares HER2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares CD137 (4-1BB, TNFRSF9) and the tag pipeline.
Shares HER2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.